Related Experiment Video

Updated: Aug 18, 2026

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
10:12

Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis

Published on: September 11, 2019

Therapy of chronic hepatitis C in the setting of HIV co-infection

P Michielsen1, E Bottieau

  • 1University Hospital Antwerp, Wilrijkstraat 10, B-2650 Edegem. peter.michielsen@uza.be

Acta Gastro-Enterologica Belgica
|April 19, 2005
PubMed

Insights

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection is common, particularly in intravenous drug users. While HCV treatment is recommended for stable HIV patients, co-infected individuals show lower sustained viral response rates.

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are significant global health concerns.
  • Shared transmission routes lead to frequent co-infection, especially among intravenous drug users.
  • HIV accelerates HCV-related liver disease progression, and HCV co-infection increases the risk of hepatotoxicity from Highly Active Antiretroviral Therapy (HAART).

Purpose of the Study:

  • To review the implications of HCV infection on HIV disease progression and HAART.
  • To discuss the current recommendations for HCV treatment in co-infected patients.
  • To analyze treatment outcomes and success factors for HCV in co-infected individuals.

Main Methods:

  • Literature review of studies on HCV/HIV co-infection and treatment outcomes.
  • Analysis of data regarding HCV treatment efficacy in co-infected versus mono-infected patients.
  • Examination of factors influencing sustained viral response to therapy.

Main Results:

  • HCV co-infection negatively impacts HIV disease progression and increases HAART hepatotoxicity risks.
  • HCV treatment is advised for stable HIV patients, with similar schedules to mono-infected individuals (pegylated interferon and ribavirin).
  • Co-infected patients demonstrate lower sustained viral response rates compared to HCV mono-infected patients, though success factors are similar.

Conclusions:

  • HCV treatment is a critical consideration for patients with stable HIV disease.
  • Further research is needed to optimize HCV treatment duration and efficacy in co-infected populations.
  • Understanding treatment outcomes is crucial for managing this complex co-infection.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...